1st Annual Iktos conference on AI for de novo drug design
Speakers
The event is over
Iktos
Incorporated in October 2016, Iktos is a company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing an innovative solution based on deep learning generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. Iktos offers its technology both as professional services and as a SaaS software platform, Makya™. Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s AI technology for retrosynthesis.
Booths
Iktos
Artificial Intelligence for new drug design
Optibrium
Elegant software that guides successful drug discovery
Simulations Plus
Top-rated science for ADMET and PK modeling
Key Organics
Chemistry, Innovation, Quality
Mcule
More than Molecules - Compound Sourcing, ULTIMATE database, Custom synthesis
Molport
End to end marketplace for chemically available compounds with free access to reliable database & powerful sourcing tools
Nanome
Collaborative virtual reality platform for molecular modeling and structure-based drug design
ChemAxon
Your scientific partner to build best-in-class software solutions for chemistry and biology.
OpenEye Scientific
OpenEye Scientific is an industry leader in computational molecular design based on decades of delivering rapid, robust, and scalable software, toolkits, and technology and design services across the drug discovery process.
QUBIT Pharmaceuticals
Revolutionising de-novo drug discovery leveraging Quantum Physics and Absolute Free-Energy of binding calculations.
SpiroChem
With SpiroChem, make the molecules you should not only the one you could!